These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 15044961)

  • 21. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of interleukin-4 on the phenotype and function of bone marrow-derived murine dendritic cells generated under serum-free conditions.
    Wells JW; Darling D; Farzaneh F; Galea-Lauri J
    Scand J Immunol; 2005 Mar; 61(3):251-9. PubMed ID: 15787742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
    Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
    Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo.
    Pulendran B; Dillon S; Joseph C; Curiel T; Banchereau J; Mohamadzadeh M
    Eur J Immunol; 2004 Jan; 34(1):66-73. PubMed ID: 14971031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer.
    Wang H; Yang G; Timme TL; Fujita T; Naruishi K; Frolov A; Brenner MK; Kadmon D; Thompson TC
    Cancer Gene Ther; 2007 Oct; 14(10):819-27. PubMed ID: 17627292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
    Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
    Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
    Yang S; Darrow TL; Vervaert CE; Seigler HF
    Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells.
    Hu J; Yuan X; Belladonna ML; Ong JM; Wachsmann-Hogiu S; Farkas DL; Black KL; Yu JS
    Cancer Res; 2006 Sep; 66(17):8887-96. PubMed ID: 16951206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granulocyte/macrophage colony-stimulating factor and interleukin-4-induced dendritic cells.
    Hikino H; Kasono K; Kanzaki M; Kai T; Konishi F; Kawakami M
    Anticancer Res; 2004; 24(3a):1609-15. PubMed ID: 15274330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines.
    Akiyama Y; Watanabe M; Maruyama K; Ruscetti FW; Wiltrout RH; Yamaguchi K
    Gene Ther; 2000 Dec; 7(24):2113-21. PubMed ID: 11223993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gender dimorphism of macrophage response to GMCSF and IL-4 for differentiation into dendritic cells.
    Gupta V; Singh SM
    Am J Reprod Immunol; 2008 Jul; 60(1):43-54. PubMed ID: 18593437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic cells genetically engineered to express IL-4 exhibit enhanced IL-12p70 production in response to CD40 ligation and accelerate organ allograft rejection.
    Kaneko K; Wang Z; Kim SH; Morelli AE; Robbins PD; Thomson AW
    Gene Ther; 2003 Jan; 10(2):143-52. PubMed ID: 12571643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines.
    Ribas A; Amarnani SN; Buga GM; Butterfield LH; Dissette VB; McBride WH; Glaspy JA; Ignarro LJ; Economou JS
    Cancer Gene Ther; 2002 Nov; 9(11):875-83. PubMed ID: 12386826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H
    Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
    Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.
    Lu J; Zhang Q; Liang CM; Xia SJ; Zhong CP; Wang DW
    Asian J Androl; 2008 Nov; 10(6):883-9. PubMed ID: 18958352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchyma.
    Hirschowitz EA; Naama HA; Evoy D; Lieberman MD; Daly J; Crystal RG
    Cancer Gene Ther; 1999; 6(6):491-8. PubMed ID: 10608345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.